Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Sanofi MS drug nears green light after pass-the-parcel marathon
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Mitoxantrone-induced suicidal erythrocyte death.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Ofatumumab Dose-finding in RRMS Patients
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Laquinimod Phase IIa Study in Active Crohn's Disease
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.

Pages